Status:
COMPLETED
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
Detailed Description
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic br...
Eligibility Criteria
Inclusion
- HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
- Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting.
- Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan 2021.
- Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
Exclusion
- Incomplete medical history
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2021
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT04850625
Start Date
January 15 2020
End Date
June 15 2021
Last Update
July 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, China, 200032